Result of GM and Capital Raising update

Eden Research plc

17 August 2023

 

17 August 2023

Eden Research

("Eden" or "the Company")

Result of General Meeting and Capital Raising update

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, is pleased to announce that all resolutions put forward to shareholders at the Company's General Meeting held earlier today were duly passed.

The total number of votes received by proxy on each resolution, as more fully disclosed in the Notice of Meeting available on the Company's website, was as follows:

#	Resolution	For	%	Against	%	Withheld
1	Grant authority to the Directors to allot Ordinary Shares	129,273,794	99.79	269,322	0.21	13,950
2	Disapply statutory pre-emption rights on allotment of shares*	129,183,794	99.72	359,322	0.28	13,950
3	Grant authority to cancel share premium account*	129,157,112	99.76	316,252	0.24	83,702

Notes:

·    * Denotes a Special Resolution.

·    A vote Withheld is not a vote in law and is not counted in the calculation of the votes cast For or Against the resolution, nor in the calculation of the percentage of issued share capital voted for any resolution.

·    Votes For and Against are expressed as a percentage of votes validly cast for that resolution by proxy, excluding any Withheld votes.

Capital Raising update

In the announcement made by the Company on 28 July 2023 regarding its Capital Raising, it was stated that "The Placing of the Conditional Placing Shares is conditional, inter alia, on (i) the approval of the Resolutions at the General Meeting, (ii) the Advanced Assurance being obtained from HMRC, (iii) the Capital Reduction becoming effective and (iv) Second Admission."

In addition to the Resolutions having been approved at the General Meeting today, the Company is pleased to confirm that it has also obtained the Advanced Assurance from HMRC required for the Conditional Placing.

The expected timetable for the satisfying the remaining conditions of the Conditional Placing is as follows:

Expected date for final hearing and confirmation of the Capital Reduction by the Court	12 September
Expected date that the Capital Reduction become effective	14 September
Second Admission	Expected second half of September
Second Admission Long Stop Date	8 a.m. on 20 October

For further information contact:

Eden Research plc	www.edenresearch.com
Sean Smith Alex Abrey	01285 359 555
Cenkos Securities plc (Nominated advisor and broker)
Giles Balleny / Max Gould (corporate finance) Michael Johnson (sales)	020 7397 8900
Hawthorn Advisors (Financial PR)
Simon Woods Felix Meston	[e-mail]

 

END